文献速递前列腺增生与排尿功能障碍

eCoin®植入式胫神经刺激治疗急迫性尿失禁安全性与有效性的两年关键研究分析

Two-year Pivotal Study Analysis of the Safety and Efficacy of Implantable Tibial Nerve Stimulation With eCoin® for Urgency Urinary Incontinence.
PubMed 文献 · Urology · 2024-07-30

这项前瞻性、多中心、单臂关键研究在137例难治性急迫性尿失禁(UUI)患者中评估eCoin植入式胫神经刺激系统(ITNS),延长随访至2年。72例完成96周评估,约78%(95%CI 67%-87%)达到UUI发作至少50%减少,48%(95%CI 36%-60%)达到至少75%减少,22%(95%CI 13%-33%)3日日记干爽;延长阶段未报告严重或非预期不良事件。

要点

  • 72例完成96周评估,约78%(95%CI 67%-87%)UUI发作较基线减少至少50%。
  • 48周与96周UUI发作/天分别较基线减少2.61(SD 2.97)与2.97(SD 2.64)。
  • 延长阶段未报告严重或非预期不良事件,约91.3%无需额外OAB药物。

核心结论

  • eCoin ITNS在治疗伴UUI的OAB患者中显示出持续一致的有效性和安全性,研究结果支持其作为难治性患者的优良治疗选择。

研究设计与样本

  • 前瞻性、多中心、单臂试验纳入137例难治性UUI受试者,评估eCoin ITNS疗法,1年关键研究延长至2年。

主要发现

  • 72例受试者完成96周评估,约78%(95%CI 67%-87%)UUI发作较基线减少至少50%。
  • 48%(95%CI 36%-60%)UUI发作较基线减少至少75%,22%(95%CI 13%-33%)3日日记干爽。
  • UUI发作/天较基线减少在48周为2.61(SD 2.97)、96周为2.97(SD 2.64)。
  • 约91.3%无需额外OAB药物,延长阶段未报告严重或非预期不良事件。

关键数值与推荐

  • 主要疗效指标为UUI发作数较基线减少至少50%的受试者比例。
  • 主要安全性指标为器械相关不良事件(AEs)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the continued effectiveness and safety of the eCoin Implantable Tibial Nerve Stimulator system (ITNS) for urgency urinary incontinence (UUI) in patients with overactive bladder (OAB). The 1-year pivotal study was extended through 2 years. The ITNS is a novel and recently FDA-approved therapy. METHODS: A prospective, multicenter, single-arm trial was conducted on 137 subjects with refractory UUI to evaluate eCoin ITNS therapy. A 3-day voiding diary was collected along with the OAB questionnaire, Patient Global Impression of Improvement, and a custom Likert scale on subject satisfaction. The primary efficacy measure was the proportion of subjects who achieved at least 50% reduction from baseline in number of UUI episodes. The primary safety measure was device-related adverse events (AEs). RESULTS: Seventy-two subjects completed the 96-week evaluation. Around 78% (95% CI: 67%-87%) experienced at least 50% reduction in UUI episodes; 48% (95% CI, 36%-60%) experienced at least 75% reduction, and 22% (95% CI, 13%-33%) were dry on a 3-day diary. Subjects reported a decrease from baseline in their UUI episodes/day of 2.61 (SD 2.97) and 2.97 (SD 2.64) at 48 weeks and 96 weeks, respectively. Around 91.3% did not require additional medications for OAB. No serious or unanticipated AEs were reported in this extension phase. CONCLUSION: The eCoin ITNS demonstrated consistent continuing effectiveness and safety in treating OAB patients with UUI. The findings support it as an excellent treatment option for refractory patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lucente V, Giusto L, MacDiarmid S, et al. Two-year Pivotal Study Analysis of the Safety and Efficacy of Implantable Tibial Nerve Stimulation With eCoin® for Urgency Urinary Incontinence. Urology. 2024. PMID: 39089497. doi:10.1016/j.urology.2024.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。